AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31242340 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleasant imagery and relaxation instruction (PIRI) video
Number of subjects: 154
Study 31242340 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 154
Study 31242340 — intervention group
Group type: COMPARATOR
Intervention: Prevention of post‐rape stress (PPRS) video
Number of subjects: 154
Study 28476486 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial scratch (ES)
Number of subjects: 299
Study 28476486 — intervention group
Group type: COMPARATOR
Intervention: Endocervical manipulation (control)
Number of subjects: 299
Study 25963311 — intervention group
Group type: EXPERIMENTAL
Intervention: Not guaranteed benefit statement
Number of subjects: 584
Study 25963311 — intervention group
Group type: COMPARATOR
Intervention: Some but very small chance benefit statement
Number of subjects: 584
Study 23707275 — intervention group
Group type: EXPERIMENTAL
Intervention: Social observational learning condition (OLC)
Number of subjects: 85
Study 23707275 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal suggestion condition (VSC)
Number of subjects: 85
Study 23707275 — intervention group
Group type: COMPARATOR
Intervention: Control condition (CC)
Number of subjects: 85
Study 21802589 — intervention group
Group type: EXPERIMENTAL
Intervention: Training (T) - 2 full days of hands-on course over a 3-month period
Number of subjects: 31
Study 21802589 — intervention group
Group type: COMPARATOR
Intervention: Control (S) - No training
Number of subjects: 31
Study 19302250 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg daily for 7 days
Number of subjects: 41
Study 19302250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 17904459 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 612
Study 17904459 — intervention group
Group type: COMPARATOR
Intervention: Control (sotalol and placebo combined)
Number of subjects: 612
Study 15779583 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised questionnaire on knowledge and attitudes towards tuberculosis
Number of subjects: 205
Study 12500362 — intervention group
Group type: EXPERIMENTAL
Intervention: New informational materials developed by the Centers for Medicare & Medicaid Services (CMS) as part of the National Medicare Education Program (NMEP)
Number of subjects: 0
Study 12500362 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 9291444 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (16 patients) or guided drug therapy (electrophysiologically guided class I antiarrhythmic drugs = 7 patients; Holter‐guided class III antiarrhythmic drugs = 16 patients)
Number of subjects: 111
Study 9291444 — intervention group
Group type: EXPERIMENTAL
Intervention: Holter‐guided class III antiarrhythmic drugs
Number of subjects: 111
Study 9291444 — intervention group
Group type: COMPARATOR
Intervention: Beta blockers
Number of subjects: 111
Study 9291444 — intervention group
Group type: COMPARATOR
Intervention: No antiarrhythmic drug therapy
Number of subjects: 111
Study 7949090 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleeding time test
Number of subjects: 118
Study 7949090 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous aspirin (500 mg)
Number of subjects: 118
Study 7949090 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (0.3 mg)
Number of subjects: 118
Study 7949090 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative bleeding time parameters
Number of subjects: 118
Study 3599793 — intervention group
Group type: EXPERIMENTAL
Intervention: One capsule t.d.s. of terpene mixture (Rowachol)
Number of subjects: 36
Study 3599793 — intervention group
Group type: EXPERIMENTAL
Intervention: Two capsules t.d.s. of terpene mixture (Rowachol)
Number of subjects: 36
Study 3599793 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 36
Study 29140959 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous proximal adductor canal block (ACB)
Number of subjects: 73
Study 29140959 — intervention group
Group type: COMPARATOR
Intervention: Continuous distal adductor canal block (ACB)
Number of subjects: 73
Study 28774331 — intervention group
Group type: EXPERIMENTAL
Intervention: Staging radioactive particle implantation guided by CT and fiber bronchoscopy
Number of subjects: 102
Study 28774331 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 102
Study 25630641 — intervention group
Group type: COMPARATOR
Intervention: Rifampicin (10 mg/kg body weight)
Number of subjects: 90
Study 25630641 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin plus 150 mg of SQ109
Number of subjects: 90
Study 25630641 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin plus 300 mg of SQ109
Number of subjects: 90
Study 25630641 — intervention group
Group type: EXPERIMENTAL
Intervention: SQ109 alone
Number of subjects: 90
Study 24014482 — intervention group
Group type: EXPERIMENTAL
Intervention: Health mentor (HM) group received regular calls from trained community health nurses.
Number of subjects: 182
Study 24014482 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC) group received GP care plus non-interventional brief phone calls.
Number of subjects: 182
Study 21372751 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP‐IPV‐Hep B‐PRP‐T vaccine (Hexaxim)
Number of subjects: 624
Study 21372751 — intervention group
Group type: COMPARATOR
Intervention: Pentaxim and Engerix B Pediatrico (Hep B monovalent) vaccines
Number of subjects: 624
Study 18201291 — intervention group
Group type: EXPERIMENTAL
Intervention: Coated graft
Number of subjects: 40
Study 18201291 — intervention group
Group type: COMPARATOR
Intervention: Uncoated graft
Number of subjects: 40
Study 15946871 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (1500 mg)
Number of subjects: 16
Study 15946871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 12816172 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease management program
Number of subjects: 406
Study 12816172 — intervention group
Group type: COMPARATOR
Intervention: Usual practice
Number of subjects: 406
Study 11347331 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (200 mg, i.v., every other day, 10 doses, total course dose 2 g)
Number of subjects: 70
Study 11347331 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone and cyclophosphamide (200 mg, i.v., on methylprednisolone-free days, 10 doses plus 200 mg i.v. once a month for 3 months, total course dose 2.6 g)
Number of subjects: 70
Study 8636283 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (goserelin, 3.6‐mg implant) for 9 months
Number of subjects: 39
Study 8636283 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (goserelin) + estrogen‐progestin replacement therapy (HRT)
Number of subjects: 39
Study 8636283 — intervention group
Group type: COMPARATOR
Intervention: GnRH agonist (goserelin)
Number of subjects: 39
Study 1334713 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (1.5 mg)
Number of subjects: 10
Study 1334713 — intervention group
Group type: COMPARATOR
Intervention: 2-Deoxyglucose (2DG, 50 mg/kg)
Number of subjects: 10
Study 6428577 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental diet (Vivonex) for four weeks
Number of subjects: 21
Study 6428577 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone 0.75 mg/kg/day for four weeks
Number of subjects: 21
Study 31655016 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoiesis stimulating agents (ESAs)
Number of subjects: 0
Study 31655016 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood withdrawal
Number of subjects: 0
Study 31655016 — intervention group
Group type: COMPARATOR
Intervention: Exercise-induced muscle damage
Number of subjects: 0
Study 28443388 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance with real-time transthoracic echocardiography and chest ultrasonography
Number of subjects: 60
Study 28443388 — intervention group
Group type: COMPARATOR
Intervention: Conventional group (CXR)
Number of subjects: 60
Study 28198972 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified step‐back technique
Number of subjects: 90
Study 28198972 — intervention group
Group type: COMPARATOR
Intervention: Rotational technique
Number of subjects: 90
Study 28198972 — intervention group
Group type: COMPARATOR
Intervention: Reciprocal technique
Number of subjects: 90
Study 28198972 — intervention group
Group type: EXPERIMENTAL
Intervention: All techniques
Number of subjects: 90
Study 25148814 — intervention group
Group type: COMPARATOR
Intervention: Routine specialty care (RSC)
Number of subjects: 28
Study 25148814 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily remote glucose monitoring (RGM)
Number of subjects: 28
Study 25148814 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 28
Study 24135012 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosphenytoin (20 phenytoin equivalents/kg)
Number of subjects: 173
Study 24135012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study 21487653 — intervention group
Group type: EXPERIMENTAL
Intervention: quetiapine (400 mg/day)
Number of subjects: 20
Study 21487653 — intervention group
Group type: COMPARATOR
Intervention: matched placebo
Number of subjects: 20
Study 18764912 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA-ethanol MDI
Number of subjects: 31
Study 18764912 — intervention group
Group type: COMPARATOR
Intervention: Baseline BEC
Number of subjects: 31
Study 17154092 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone iv pulse therapy
Number of subjects: 0
Study 17154092 — intervention group
Group type: COMPARATOR
Intervention: Glucocorticoids (small doses and short periods)
Number of subjects: 0
Study 17154092 — intervention group
Group type: COMPARATOR
Intervention: High dose of pulse therapy (9-12g)
Number of subjects: 0
Study 17154092 — intervention group
Group type: COMPARATOR
Intervention: Cumulative dose limited to 4.5-6g
Number of subjects: 0
Study 14550588 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetic-acid visualization (VIA)
Number of subjects: 12992
Study 14550588 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnified acetic-acid visualization (VIAM)
Number of subjects: 12992
Study 14550588 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatula+cotton swab‐Papanicolaou (Pap) smear (SS)
Number of subjects: 12992
Study 14550588 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical brush‐Pap smear (CB)
Number of subjects: 12992
Study 11069196 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg risedronate daily for 2 weeks
Number of subjects: 0
Study 8619935 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen treatment in ER positive subgroup
Number of subjects: 98
Study 8619935 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant tamoxifen treatment in ER negative subgroup
Number of subjects: 98
Study 1345799 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir
Number of subjects: 234
Study 1345799 — intervention group
Group type: COMPARATOR
Intervention: Foscarnet
Number of subjects: 234
Study 1345799 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 234
Study 6421395 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular physical exercise for two months
Number of subjects: 31
Study 6421395 — intervention group
Group type: COMPARATOR
Intervention: Control group (29 men)
Number of subjects: 31
Study 29722250 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscular Hypertrophy (MH) training
Number of subjects: 23
Study 29722250 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscular Endurance (ME) training
Number of subjects: 23
Study 29609254 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive intervention group
Number of subjects: 799
Study 29609254 — intervention group
Group type: EXPERIMENTAL
Intervention: Health literacy intervention group
Number of subjects: 799
Study 29609254 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention group
Number of subjects: 799
Study 29609254 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 799
Study 26888587 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) treatment for 4 weeks
Number of subjects: 36
Study 26888587 — intervention group
Group type: COMPARATOR
Intervention: Control group (rehabilitation treatment as usual)
Number of subjects: 36
Study 24628923 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (doses between 75 and 260 U, average 163 U per treatment cycle, administered every 12 weeks)
Number of subjects: 2436
Study 24628923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2436
Study 22333336 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief alcohol intervention
Number of subjects: 152
Study 22333336 — intervention group
Group type: COMPARATOR
Intervention: Attention-placebo control
Number of subjects: 152
Study 19734008 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Tampa Scale for Kinesiophobia (11 items out of 16)
Number of subjects: 347
Study 19734008 — intervention group
Group type: COMPARATOR
Intervention: Original Tampa Scale for Kinesiophobia (17 items)
Number of subjects: 347
Study 18034980 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine hydrochloride nasal spray, 665 mcg (OLO)
Number of subjects: 425
Study 18034980 — intervention group
Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 425
Study 18034980 — intervention group
Group type: COMPARATOR
Intervention: Mometasone furoate monohydrate, 50 mcg (MM)
Number of subjects: 425
Study 16273964 — intervention group
Group type: EXPERIMENTAL
Intervention: High job strain
Number of subjects: 0
Study 16273964 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest strain-ratio category
Number of subjects: 0
Study 16273964 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest job-strain ratio category with low previous computer use
Number of subjects: 0
Study 16273964 — intervention group
Group type: COMPARATOR
Intervention: Low job strain
Number of subjects: 0
Study 11900102 — intervention group
Group type: EXPERIMENTAL
Intervention: Change-detection paradigm using objects defined by color with location or shape
Number of subjects: 0
Study 11900102 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused attention
Number of subjects: 0
Study 11900102 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated format of visual memory
Number of subjects: 0
Study 9927369 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled lidocaine
Number of subjects: 15
Study 9927369 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Number of subjects: 15
Study 9927369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 7558529 — intervention group
Group type: EXPERIMENTAL
Intervention: 3‐5 sets of 10 maximal concentric actions on an accommodating resistance device
Number of subjects: 12
Study 7558529 — intervention group
Group type: EXPERIMENTAL
Intervention: 3‐5 sets of 8‐12 coupled eccentric/concentric actions on a weight training device
Number of subjects: 12
Study 7558529 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic dynamometer training
Number of subjects: 12
Study 7558529 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scans measuring cross-sectional area
Number of subjects: 12
Study 7558529 — intervention group
Group type: EXPERIMENTAL
Intervention: Biceps type I and II fiber area measurements
Number of subjects: 12
Study 2075140 — intervention group
Group type: EXPERIMENTAL
Intervention: Alugastrin (30 mL liquid form)
Number of subjects: 0
Study 2075140 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrin (tablet form)
Number of subjects: 0
Study 2075140 — intervention group
Group type: EXPERIMENTAL
Intervention: Wikalina (tablet form)
Number of subjects: 0
Study 2075140 — intervention group
Group type: EXPERIMENTAL
Intervention: Alusal (other brand)
Number of subjects: 0
Study 2075140 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnosil (other brand)
Number of subjects: 0
Study 2075140 — intervention group
Group type: COMPARATOR
Intervention: Maalox (control)
Number of subjects: 0
Study 7459426 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered tablet formulation of oxyphenbutazone
Number of subjects: 0
Study 7459426 — intervention group
Group type: COMPARATOR
Intervention: Commercially available product of oxyphenbutazone
Number of subjects: 0
Study 31225984 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic clinical trial data extraction modules
Number of subjects: 281
Study 31225984 — intervention group
Group type: COMPARATOR
Intervention: Synthetic clinical trial
Number of subjects: 281
Study 28614691 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amphotericin B deoxycholate (0.7 to 1.0 mg/kg/day)
Number of subjects: 440
Study 28614691 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole capsules (600 mg/day for 3 days, then 400 mg/day for 11 days)
Number of subjects: 440
Study 25679199 — intervention group
Group type: EXPERIMENTAL
Intervention: e-learning supported Train-the-Trainer programme
Number of subjects: 45
Study 25679199 — intervention group
Group type: COMPARATOR
Intervention: Traditional guideline dissemination
Number of subjects: 45
Study 23124692 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT) procedure
Number of subjects: 0
Study 23124692 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT) procedure with concomitant cystocele repair
Number of subjects: 0
Study 21074150 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel intrauterine system (LNG‐IUS)
Number of subjects: 75
Study 21074150 — intervention group
Group type: COMPARATOR
Intervention: Hysterectomy
Number of subjects: 75
Study 19601705 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg once daily for 4 weeks
Number of subjects: 356
Study 19601705 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid use
Number of subjects: 356
Study 16183201 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler sonography in Parkinsonian patients
Number of subjects: 47
Study 16183201 — intervention group
Group type: COMPARATOR
Intervention: Doppler sonography in age and sex matched controls
Number of subjects: 47
Study 16183201 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler parameters in patients within each Hoehn‐Yahr scale
Number of subjects: 47
Study 16183201 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of patient age and disease duration with Doppler parameters
Number of subjects: 47
Study 16183201 — intervention group
Group type: EXPERIMENTAL
Intervention: Values of vertebral, internal carotid and cerebral blood flow volumes (CBF), peak systolic velocities, and cross‐sectional areas
Number of subjects: 47
Study 11954943 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil (100 microg/kg)
Number of subjects: 32
Study 11954943 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 32
Study 10369154 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed patients
Number of subjects: 20
Study 10369154 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 20
Study 10369154 — intervention group
Group type: COMPARATOR
Intervention: Recovered patients
Number of subjects: 20
Study 7730925 — intervention group
Group type: EXPERIMENTAL
Intervention: Academic group detailing by pharmacists, 4 sessions
Number of subjects: 134
Study 7730925 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 134
Study 2183543 — intervention group
Group type: EXPERIMENTAL
Intervention: beclamide
Number of subjects: 23
Study 2183543 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 23
Study 6104743 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenalterol (beta 1‐adrenoceptor agonist)
Number of subjects: 0
Study 31915060 — intervention group
Group type: EXPERIMENTAL
Intervention: Media Aware, a web-based comprehensive sexual health promotion program
Number of subjects: 0
Study 31915060 — intervention group
Group type: COMPARATOR
Intervention: Standard health education programming (delayed intervention group)
Number of subjects: 0
Study 29615092 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based metacognitive therapy plus usual cardiac rehabilitation
Number of subjects: 332
Study 29615092 — intervention group
Group type: COMPARATOR
Intervention: Usual cardiac rehabilitation alone
Number of subjects: 332
Study 28830536 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week bounding exercise programme (BEP) consisting of functional plyometric exercises
Number of subjects: 0
Study 28830536 — intervention group
Group type: COMPARATOR
Intervention: Regular soccer training
Number of subjects: 0
Study 28830536 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week bounding exercise programme (BEP)
Number of subjects: 0
Study 25275411 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservative-free fixed dose combination of tafluprost 0.0015% and timolol 0.5%
Number of subjects: 28
Study 25275411 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservative-free non-fixed combination of tafluprost 0.0015% and timolol 0.5%
Number of subjects: 28
Study 24066341 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite graft (rhBMP-2/ACS, CCFDAB, PRP)
Number of subjects: 20
Study 24066341 — intervention group
Group type: COMPARATOR
Intervention: 100% autogenous graft
Number of subjects: 20
Study 24066341 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite graft
Number of subjects: 20
Study 24066341 — intervention group
Group type: COMPARATOR
Intervention: Autogenous graft
Number of subjects: 20
Study 24066341 — intervention group
Group type: EXPERIMENTAL
Intervention: Both grafts
Number of subjects: 20
Study 21946361 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (FLX) 20 mg for 8 weeks
Number of subjects: 23
Study 21946361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 18713545 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser therapy in addition to traditional therapy
Number of subjects: 60
Study 18713545 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser therapy
Number of subjects: 60
Study 18713545 — intervention group
Group type: COMPARATOR
Intervention: Traditional therapy
Number of subjects: 60
Study 18713545 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal skin)
Number of subjects: 60